How profitable is TherapeuticsMD Inc. (TXMD)?

In FY 2025 (10-K), TXMD converted $12.3M of revenue into a 52% gross margin, 0% operating margin, and $583348 in free cash flow (4.7% FCF margin).

Stock Ratings / Health Care / TXMD / financials

AYTU (27) QNTM (46) ATOS (33) QNRX (37) ⌘ Pro Terminal →

TherapeuticsMD Inc. (TXMD) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.81 +0.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.81

TherapeuticsMD Inc. (TXMD) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $20.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TXMD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TXMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, TherapeuticsMD Inc. (NASDAQ: TXMD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.81 (+0.56% 1D, market cap $20.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TXMD ranks #647 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TXMD compare to AYTU and QNTM in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TXMD carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -12.9%. By comparison, AYTU (Aytu BioPharma Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $21.0M) and QNTM (Quantum Biopharma Ltd. Class B Subordinate Voting Shares) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $20.2M). Among the 5-stock peer group, TXMD leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TXMD?

▼

Per TXMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000025743), TherapeuticsMD Inc. generated $12.3M in revenue (+598.0% YoY), -$569.0K in net income, and $0 in free cash flow against $37.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.81 (-0.09%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 4.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TXMD)Realized 20D OHLCV Swing Band: ±7%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY TXMD SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 38% of 52W Range • RSI-14 at 35.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.96-4.1% Next Q

Q2 (-2Q)

Grade E$1.88-5.3% Next Q

Q3 (-1Q)

Grade E$1.78+1.7% Next Q

Current

Grade E$1.81-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TXMD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TXMD currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.04) and Max Pain ($1.90) forces dealer call-delta covering toward $3.10.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TXMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TXMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How TXMD Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$583.3K (4.7% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $1.3M

FY24

Rev $1.8M

FY25

Rev $12.3M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$12.3M	52%	-35.7%	-$569.0K	-$540.5K	-12.9%
FY 2024	$1.8M	52%	-80%	-$2.2M	-$2.1M	-21.6%
FY 2023	$1.3M	52%	-80%	-$10.3M	-$9.8M	-12.9%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TXMD)

✓Walkthrough of TXMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TXMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -10.40%▼ DESCENDING CHANNEL

2026-11-03O $1.83H $1.83L $1.80C $1.81VOL 3.8K

RES: $2.22SUP: $1.69SMA50: $2.04SMA200: $2.11

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TXMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TXMD Butterfly Map → + Track TXMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TXMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TXMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TXMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TXMD)

Health Care Rank #647 of 1016 ⚔️ AYTU vs TXMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TXMD vs. AYTU, QNTM, ATOS, QNRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, TherapeuticsMD Inc. (TXMD) ranks #647 by composite RQD confidence (34/100, grade E) and #829 by equity capitalization ($20.8M). Within this direct 5-issuer industry benchmark cohort, TXMD leads on earnings valuation at N/A trailing P/E, while TXMD leads on capital efficiency and profitability with -12.9% ROIC and — gross margin. QNTM currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with TXMD at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TXMD ACTIVE TherapeuticsMD Inc.	E	34/100	—	—	-12.9%	+0.56%	$20.8M	Benchmark Subject
AYTU Aytu BioPharma Inc.	E	27/100	—	69.0%	-35.0%	+0.52%	$21.0M	/aytu-vs-txmd →
QNTM Quantum Biopharma Ltd. Class B Subordinate Voting Shares	D	46/100	—	—	—	-5.04%	$20.2M	/qntm-vs-txmd →
ATOS Atossa Therapeutics Inc.	E	33/100	—	—	-35.0%	+5.99%	$21.7M	/atos-vs-txmd →
QNRX Quoin Pharmaceuticals Ltd.	D-	37/100	—	—	-35.0%	-11.45%	$21.8M	/qnrx-vs-txmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000025743

In its most recent audited fiscal period (FY2025, filed 2025-12-31), TherapeuticsMD Inc. (TXMD) reported GAAP revenue of $12.3M (+598.0% vs. FY2024 revenue of $1.8M , and +844.1% cumulative change since FY2023) , GAAP net income of -$569.0K, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, TXMD closed FY2025 with $37.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$12.3M	-$569.0K	—	—	$37.7M	—
FY2024 (FY)	2024-12-31	$1.8M	-$2.2M	—	—	$38.8M	—
FY2023 (FY)	2023-12-31	$1.3M	-$10.3M	—	—	—	—

3. TXMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TXMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does TXMD compare to AYTU and QNTM in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for TXMD?

Where is TXMD trading relative to its 50-day, 200-day, and 52-week technical levels?

TXMD last traded at $1.81 (+0.56% on volume of 8,528 shares), positioning the stock -11.27% below its 50-day simple moving average ($2.04) and -14.22% below its 200-day simple moving average ($2.11). Across its 52-week range of $1.11 to $2.95, TXMD sits at the 38.0% percentile with a 14-day RSI of 35.4 (NEUTRAL RANGE) and an implied next-earnings move of ±7.0% ($1.68 to $1.94).

Direct Sub-Reports: TXMD RQD Cockpit TXMD 12M Forecast TXMD Earnings & Move TXMD Dividends & DRIP TXMD Insiders & 13F TXMD Whale Options TXMD Profit Sankey TXMD News & Why

ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

TXMD — TherapeuticsMD Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:49:45Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

TXMD scores 34 out of 100, earning a grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The score is the sum of five pillars, each weighted out of 20:

Fundamental Cash Engine: 7 / 20. The rating cites ROIC of -12.9% and an FCF yield of 0%. For a prospective investor, this means the business is not currently generating a return on invested capital or free cash flow that would support the share price on cash-based valuation.
Whale 13F Flow: 4 / 20. This pillar reflects institutional accumulation and options positioning. A low score indicates weak institutional support in the source data.
Insider Conviction: 5 / 20. This pillar draws on SEC Form 4 and Congressional PTR cluster flow. The low score signals limited evidence of insider or cluster conviction.
Macro Regime Fit: 8 / 20. The rating shows a beta of 1.0 and a sector sensitivity profile. This pillar offers little differentiation; the stock's market sensitivity is neutral, but the score reflects weak fit with the prevailing regime per the rating's methodology.
Forensic Balance Sheet: 10 / 20. The rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. The Piotroski reading is weak, and the Altman figure is the strongest forensic datapoint in the set.

Investor implications: the upside case rests on any future improvement in operating performance that could lift ROIC and cash generation from negative territory; the valuation tradeoff is that with no positive earnings or free cash flow in the source data, the stock trades on factors outside the reported cash engine. The lowest-scoring pillars (Insider Conviction and Whale 13F Flow) suggest the market's most informed participants are not signaling conviction. The balance sheet pillar is middling rather than distressed, which means solvency is a less immediate concern than profitability.

2. Business Model, Unit Margins & SEC Financial Trajectory

TherapeuticsMD Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It is a biotechnology/pharmaceutical preparations company. Specific products, customers, and revenue model details are —

Revenue declined from $1.8M in FY 2024 to — in FY 2025, and operating losses narrowed from -$6.1M to -$4.4M over the same span. Gross, operating, and net margins are each reported as 0% in the market data. ROIC is -12.9%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with a Debt/Equity ratio of 0.5. These figures describe a company reporting no revenue in its latest fiscal year and continuing operating losses.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Altman Z-Score of 2.5 and Debt/Equity of 0.5 indicate a balance sheet that is middling rather than distressed, with a 52-week low of $1.11 below the current $1.83 price. With Fundamental Cash Engine at 7/20 (ROIC -12.9%, FCF yield —) and Institutional Whale Flow at 4/20, sustained execution supports upside toward the top of the $1.11 – $2.95 52-week range.
🐻 Primary Bear Case: Revenue fell to $0.0M in FY 2025 with operating losses of -$4.4M, ROIC of -12.9%, and FCF yield of 0%, against a Piotroski F-Score of 2/9. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are —

Key Question #1: What specific products or pipeline assets generate the company's revenue, and what drove the drop from $1.8M to — in FY 2025?
Key Question #2: What are the cash, debt, EPS, and free cash flow figures for each reported period, which are currently N/A in the financial data?
Key Question #3: What is the company's cash runway given a $21.2M market capitalization and continuing operating losses?

TXMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for TherapeuticsMD Inc. (TXMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TXMD Debate Forum (3) ↓

🟡 MARKET WIRE Barron's • 20h ago

TherapeuticsMD Inc. Advanced Charts | TXMD

Barron's report covering TherapeuticsMD Inc. (TXMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketWatch • 23h ago

TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors

MarketWatch report covering TherapeuticsMD Inc. (TXMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketWatch • 1d ago

TherapeuticsMD Inc. stock underperforms Monday when compared to competitors

MarketWatch report covering TherapeuticsMD Inc. (TXMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST MarketWatch • 1d ago

TherapeuticsMD Inc. stock outperforms competitors on strong trading day

MarketWatch report covering TherapeuticsMD Inc. (TXMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 83d ago

TherapeuticsMD Announces Second Quarter 2026 Financial Results

BOCA RATON, Fla., August 11, 2026--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months en

Read Full Source ↗

🔴 RISK WATCH siam.in • 18d ago

TXMD Q3 2023 Earnings: Loss Per Share Widens Past Consensus as Shares Slip - Earnings Decline Risk

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNOFg5YjAxWUZkczluSGdVWXZ0aFZvMlpuVDhzRlpPWmJ0WE1KRFQzNExJek5xTXdvSmpqYl9EVFBDdkxDelBYdmpzdkF6MFFWaFRNOEtiZGszTkhFaVVhUUppWXVLRTRueUUteGoyZjQ1UEgtR2pScXRrelJ

Read Full Source ↗

🔴 RISK WATCH https://www.siam.in/ • 5d ago

TXMD Q3 2023 Earnings: Wider-Than-Expected Loss Per Share Draws Attention Despite Modest Stock Uptick - Forward Guidance Trends

<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxQam5QX3JNbGhZNEE3cVluN2xUWDRtQmdTM1lpZEdHMGh1SDVFalVVSjFUQWN3YXlZNHdsallwb0xWdTdOYUtaWF9GVDNFN1E2aS11YjhRdXoxbEFuQ185MUpTdDYtcDlTVUp4UVVpV2R0NjMwNUlJeUJBRGR

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TXMD Bull vs. Bear Conversation Board — What's Your Call at $1.81?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TXMD 🐻 33% BEARISH CONVICTION

CA CashFlowKing FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $2.16 (+20.0%)

📌 Pinned Debate

Altman Z-Score of 2.5 and Debt/Equity of 0.5 indicate a balance sheet that is middling rather than distressed, with a 52-week low of $1

Long TXMD at $1.80 targeting $2.16. Altman Z-Score of 2.5 and Debt/Equity of 0.5 indicate a balance sheet that is middling rather than distressed, with a 52-week low of $1.11 below the current $1.83 price.. Institutional whale score is 4/20 and the risk/reward vs. the $1.11 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

@RiskArb_Desk Shorting a 4/20 institutional whale-flow stock at $1.80 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk Hedged Event Driven 🐻 BEARISH 🎯 Target: $1.37 (-23.9%)

Spot @ $1.80

Revenue fell to $0.0M in FY 2025 with operating losses of -$4.4M, ROIC of -12.9%, and FCF yield of 0%, against a Piotroski F-Score of 2

Fading this rally in TXMD at $1.80. Revenue fell to $0.0M in FY 2025 with operating losses of -$4.4M, ROIC of -12.9%, and FCF yield of 0%, against a Piotroski F-Score of 2/9.. With a beta of 1.0 and the stock sitting at $1.80 (52-wk range $1.11–$2.95), the easy multiple expansion is already priced in.